Cluster Analysis of the Risk of Metabolic Syndrome in Women for Reproductive Age
|ClinicalTrials.gov Identifier: NCT01826357|
Recruitment Status : Unknown
Verified November 2013 by Ming-I Hsu, Taipei Medical University WanFang Hospital.
Recruitment status was: Recruiting
First Posted : April 8, 2013
Last Update Posted : November 6, 2013
The metabolic syndrome (MetS) is a cluster of clinical indices that signals increased risk for cardiovascular disease and Type 2 diabetes. Women with polycystic ovary syndrome (PCOS) were associated with MetS and insulin resistance. Cluster analysis was a useful tool for identifying groups of women sharing similar metabolic risk factor patterns. Oligomenorrhea, hyperandrogenism and polycystic ovary morphology were the three major components of PCOS. Obesity is a main risk factor in metabolic syndrome. the investigators are interesting to evaluate the relationship between risk of metabolic syndrome and their clinical and/or biochemical characteristics in women with reproductive age.
Design: Retrospective study; medical records reviewed. Participants and setting: The investigators retrospectively reviewed the medical records of female patients who visited our Reproductive Endocrinology Clinic from Jan. 1, 2009 to Jun. 31, 2012.
|Condition or disease|
|Metabolic Cardiovascular Syndrome|
|Study Type :||Observational|
|Estimated Enrollment :||700 participants|
|Official Title:||Cluster Analysis of the Risk of Metabolic Syndrome in Women for Reproductive Age.|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||February 2014|
|Estimated Study Completion Date :||February 2014|
- metabolic syndrome [ Time Frame: Retrospectively reviewed the patients who visited Reproductive Endocrinology Clinic from Jan. 1, 2009 to Jun. 31, 2012. ]We conduct this retrospective study by using cluster analysis, to investigate the relationship between metabolic complications and biochemical/clinical characteristics of endocrinologic dysfunction in women with reproductive age.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01826357
|WanFang Medical Center at Taipei Medical University||Recruiting|
|Taipei City, Taiwan, 116|
|Contact: Ming I Hsu, MD 886-2-2930-7930 ext 2508 firstname.lastname@example.org|
|Principal Investigator:||Ming I Hsu, MD||WanFang Medical Center at Taipei Medical University|